---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-034187"
form_type: "8-K"
ticker: "SHC"
cik: "0001822479"
company_name: "Sotera Health Co"
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:34:04.795181+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sotera Health reaffirms 2022 guidance, plans $425M Term Loan B to fund $408M EO litigation settlement

## Summary
- Reaffirms 2022 net revenue guidance of $995M-$1.005B and Adjusted EBITDA of $500M-$510M.
- Expects 2022 net loss of $226M-$236M including a $408M legal reserve for ethylene oxide settlement.
- Plans $425M Term Loan B facility to fund $408M EO settlement, pay down revolver, and boost liquidity.
- Preliminary estimates subject to completion of year-end closing; final results expected February 28, 2023.

## SEC filing metadata
- accession: 0001193125-23-034187
- form_type: 8-K
- ticker: SHC
- cik: 0001822479
- company_name: Sotera Health Co
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/0001193125-23-034187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/d428886d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-034187
- JSON: https://secwatch.observer/filing/0001193125-23-034187.json
- Plain text: https://secwatch.observer/filing/0001193125-23-034187.txt

## Key facts
- Earnings Releases
  Sotera Health Co reported the year ended December 31, 2022 results: revenue $995 million to $1.005 billion, net income $226 million to $236 million. Guidance reaffirmed.
  - Period: the year ended December 31, 2022
  - Revenue: $995 million to $1.005 billion
  - Net income: $226 million to $236 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: The Company is reaffirming its expectation that 2022 full-year net revenues will be within the previously announced guidance range of $995 million to $1.005 billion. The Company also is announcing that the 2022 full-year net loss is expected to be in a range of $226 million to $236 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/0001193125-23-034187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.